http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102346188-B
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_279b4c171d4ef5996ccd96c093a55ddf |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-577 |
| filingDate | 2010-08-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2014-07-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fa0e09e3ba28c79e1301c36528accc5b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3d9c3db8a624401dc4945001fa59a06f |
| publicationDate | 2014-07-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-102346188-B |
| titleOfInvention | Novel purpose of THBS-1 |
| abstract | The invention discloses a novel purpose of THBS-1, which is an application of thrombospondin 1 (THBS-1) in designing and/or preparing kits used for diagnosing prostate cancer. THBS-1 concentration is tested by using THBS-1 monoclonal antibody or a kit used for testing THBS-1, and then prostate cancer is diagnosed. As a result, a positive diagnostic efficiency of prostate cancer is 100%. Moreover, with the method, PSA negative (wherein a serum PSA level is lower than 10ng/ml) prostate cancer patients are diagnosed as positive. Therefore, the precision of the method is substantially higher than that of the existing PSA diagnostic method. |
| priorityDate | 2010-08-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 31.